Expression of Cyp2c8 Enzyme in Non-Small Cell Lung Cancer with 6α-Hydroxy Paclitaxel Drug by Flow Cytometric Technique Hassan Firas A.* Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq *Corresponding Author: Firas A. Hassan, E-mail: firas.hassan2014@yahoo.com
Online published on 30 April, 2019. Abstract Flow cytometry is a way of quantitative elementary cell dissection, a laser or resistance, using in cell sorting, cell counting and biomarker revelation. Cytochrome P450 “CYP” enzymes metabolize carcinogens to inefficient derivatives, however, sometimes the behavior of “CYP” enzymes leads to development of more effective carcinogens. CYP enzymes are also implicated in the activation or inactivation of operators, which are used in the therapy of lung cancer. Paclitaxel drug a high sublime performance in non-small cell lung tumor (H1299) by measured half maximal restrained concentration IC50 value was 94.48 μg/ml by compared with normal cells IC50 value was 213.6 μg/ml. Flow cytometric analysis of paclitaxel drug cause cumulation of H1229 cells at G1 phase at 5, 10, and 15 μg/ml concentrations. 6α-hydroxy paclitaxel exhibit cell cycle detention across H1299 and maximum concentration at 10 that high influenced on G1 phase accumulation in H1299 cell cycle. Top Keywords Paclitaxel, flow cytometric technique, statistical analyses, cytochrome P450 (CYP2C8). Top |